Oncology Medical Billing: What American Oncology Network Teaches Independent Practices
Oncology is the hardest specialty in medicine to bill correctly. A single patient visit can involve an evaluation and management (E/M) service, a multi-drug infusion, injectable biologics, supportive care drugs, lab work and imaging, all under different payer rules. Get one modifier, one drug unit or one authorization wrong, and a claim worth thousands of dollars is denied or underpaid.
That is why oncology medical billing deserves its own strategy, and why many independent physicians study how large community networks such as the American Oncology Network run their revenue operations. In this guide we break down what makes oncology billing so complex, which codes matter most, and how your practice can protect revenue whether you stay independent or consider joining a network.
This article is educational and is not legal, financial or investment advice. Payer policies change often, so always verify against current CMS and payer guidance.
Why Oncology Medical Billing Is Different From Every Other Specialty
Most specialties bill primarily for professional services. Oncology practices also act as small pharmacies and infusion centers. That creates three financial pressures:
- High drug cost. Chemotherapy and immunotherapy drugs are often the largest expense a practice carries. If a claim is denied, the practice has already paid for the drug.
- Complex, changing coding. New drugs, biosimilars and HCPCS J-codes are added every quarter, and units must match the vial size, dose and any waste.
- Heavy payer oversight. Prior authorization, step therapy and medical necessity edits apply to many oncology drugs and regimens.
According to industry benchmarks, specialty practices with in-house billing commonly lose a meaningful share of potential collections to preventable denials and unworked accounts. In oncology, where each claim is large, the dollar impact is larger.
Who Is American Oncology Network?
American Oncology Network (AON) is a physician-led network of community oncology practices headquartered in Fort Myers, Florida. It supports independent oncologists with shared services, including administrative support, revenue cycle operations, pharmacy and laboratory capabilities, while keeping care in the community setting where many patients prefer to be treated.
AON became a publicly traded company in 2023 and trades on Nasdaq under the ticker AONC. If you are researching the company as a potential employer, partner or investment, check current SEC filings and live market data rather than relying on any article for numbers.
For physicians, the takeaway is not the stock. It is the model: centralized, specialized revenue cycle management lets oncologists focus on patients while experts handle billing. You do not need to join a network to get that benefit. Many practices get the same advantage by outsourcing to a specialty billing partner.
AON Fort Myers and the Rise of the Oncology Physician Network
Searches for “AON Fort Myers” usually come from physicians who want to understand how a regional hub supports its member practices. The pattern behind any successful oncology physician network is consistent:
- Standardized billing workflows across every location, so a chemo infusion is coded the same way in every office.
- Scale in payer negotiations, which individual practices rarely have.
- Shared compliance and audit support, which lowers the risk of recoupments.
- Data visibility into denial rates, days in accounts receivable and net collection rate.
A smaller practice can copy items 1, 3 and 4 without giving up independence. That is exactly what a specialized oncology billing partner provides.
The Onc Network Model: Where Revenue Is Won or Lost
Whether you call it an onc network, an affiliation or a management services arrangement, the revenue cycle follows the same stages. Problems at any stage reduce what you collect.
1. Insurance Verification and Prior Authorization
Before treatment starts, verify eligibility, benefits, the drug’s coverage criteria and whether authorization is required. Oncology authorizations are often tied to a specific diagnosis, regimen and number of cycles. A missed authorization is one of the most common reasons for a full-claim denial.
2. Charge Capture
Every administered drug, every infusion hour, every push and every supportive medication must be captured. Charge capture errors in infusion suites are common because nursing documentation and the billing system may not match. A monthly reconciliation of the drug dispensing log against billed units quickly exposes lost revenue.
3. Coding and Documentation
Coding translates clinical documentation into claims. For oncology, that means accurate ICD-10 cancer diagnoses (including primary versus secondary sites), CPT administration codes, HCPCS drug codes and correct modifiers. We cover this in depth below.
4. Claim Submission and Denial Management
Clean claims go out fast. Denied claims need root-cause analysis, not just resubmission. Tracking denials by payer, drug and reason code shows patterns you can fix upstream.
5. Payment Posting and Patient Collections
Oncology patients often face large out-of-pocket costs. Clear financial counseling, payment plans and assistance program referrals protect both the patient and your collections.
CPT Code for Chemo Infusion: The Core Codes Every Oncology Practice Must Know
If you search for the CPT code for chemo infusion, the answer depends on the route, duration and sequence. The chemotherapy administration family sits in the 96401-96549 range. The most commonly used codes include:
| CPT Code | Description |
|---|---|
| 96413 | Chemotherapy administration, IV infusion; up to 1 hour, single or initial substance/drug |
| 96415 | Each additional hour of chemotherapy infusion (add-on code) |
| 96417 | Each additional sequential infusion of a different substance/drug, up to 1 hour (add-on) |
| 96409 | Chemotherapy administration, IV push; single or initial substance/drug |
| 96411 | Each additional IV push of a different substance/drug (add-on) |
| 96401 | Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic |
| 96402 | Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic |
| 96523 | Irrigation of implanted venous access device for drug delivery |
The drug itself is billed separately using a HCPCS J-code (or other drug code), with units matching the dose administered.
Common Chemo Infusion Coding Mistakes
- Using 96365 instead of 96413. Codes 96365-96379 are for therapeutic, prophylactic and diagnostic infusions. When a drug is a chemotherapy or complex biologic agent, the 96401-96549 family generally applies. Hierarchy rules decide which code is primary on the claim.
- Billing infusion time that was not documented. Start and stop times must be in the record. Add-on hours require the full time threshold to be met.
- Missing drug waste modifiers. Payers, including Medicare, require the JW modifier for discarded drug from single-dose containers, and the JZ modifier when there is no waste.
- Incorrect sequencing. Only one initial service per category is typically reported per encounter, with the remaining drugs reported as sequential or add-on codes.
- Hydration and supportive drugs billed incorrectly. Hydration infusions given concurrently with chemo are generally not separately payable, and rules vary by payer.
Medical Oncology Coding: Accuracy Starts With Documentation
Medical oncology coding is only as good as the chart behind it. Strong coding programs focus on four documentation habits.
Specify the cancer fully. ICD-10 coding requires the site, laterality where applicable, histology when it affects coding, and whether the cancer is primary, secondary (metastatic), in remission or history of. Vague diagnoses lead to medical necessity denials.
Link the drug to the diagnosis. Many payers apply local coverage determinations and compendia-based rules. The diagnosis on the claim must support the drug billed.
Document E/M separately and clearly. An E/M visit on the same day as chemo administration needs modifier 25 and a separately identifiable service. Auditors look closely at this pairing.
Record the full treatment plan. Cycle number, dose, body surface area, dose adjustments and reasons for delays help justify both the drug billed and the services provided.
Because oncology coding is so specialized, many practices find that certified coders with oncology experience reduce denials significantly compared with general coders.
Medical Oncology Billing: Denials, Underpayments and Compliance
Medical oncology billing carries risks beyond simple denial. Practices must also watch for:
- Underpayments. Drug reimbursement is often based on average sales price (ASP) plus a percentage, and payer contracts vary. Without payment variance reporting, underpayments go unnoticed.
- Biosimilar and drug-switch rules. Payers increasingly prefer biosimilars, which affects what is covered and at what rate.
- Value-based programs. CMS has tested oncology care models, such as the Enhancing Oncology Model, which tie payment to quality, episode cost and reporting requirements.
- Audit exposure. High-dollar drug claims draw review. Strong documentation and consistent coding are your best defense.
- MIPS reporting. Oncology practices must also report quality measures to avoid negative payment adjustments.
Oncology Billing Services: In-House, Outsourced or Network?
Every oncology practice eventually weighs three options.
| Option | Pros | Cons |
|---|---|---|
| In-house billing team | Direct control, on-site staff | Hiring, training, turnover, software and compliance costs |
| Joining a network or MSO | Scale, shared infrastructure | Loss of some autonomy, long-term agreements |
| Outsourced oncology billing services | Specialty expertise, scalable cost, you stay independent | Requires choosing a transparent, experienced partner |
For many independent oncologists, oncology billing services from a specialized partner deliver most of the benefits of a network without giving up ownership or decision-making.
Medical Oncology Billing Services: What to Look for in a Partner
Not every billing company can handle oncology. When you evaluate medical oncology billing services, ask these questions:
- Do you have certified coders who work specifically with oncology and infusion claims?
- How do you handle prior authorization and eligibility verification?
- Can you reconcile drug inventory against billed units and J-code units?
- How do you report denial rates, days in A/R and net collection rate?
- Is pricing transparent? Flat-fee pricing is easier to predict than percentage-based models that can grow with your revenue.
- Are you HIPAA compliant, and how do you secure patient data?
- Will you work inside our EHR and practice management system?
- Can you support credentialing, MIPS reporting and denial appeals?
How Mediflows Billing Solutions Supports Oncology Practices
Mediflows Billing Solutions provides end-to-end revenue cycle support for oncology and hematology practices, built around the problems described above. Our services include:
- Medical billing services with clean claim submission and fast follow-up
- Medical coding by experienced coders for chemo administration, drug units and modifiers
- Insurance eligibility and prior authorization support
- Denial management services that identify root causes and recover aged claims
- Credentialing and enrollment with commercial and government payers
- Quality Payment Program (MIPS) reporting
- Revenue cycle management with transparent reporting
We serve more than 30 specialties, including oncology and hematology, and we offer a flat-fee approach, so your billing cost does not rise just because your collections do.
A Practical Checklist for Oncology Practices
Use this list to review your current process:
- Prior authorization is confirmed before every new regimen and cycle
- Infusion start and stop times are documented for every administration
- Drug units and waste (JW/JZ) are reconciled monthly against inventory
- Modifier 25 usage on same-day E/M visits is audited quarterly
- Denials are tracked by payer, drug and reason code
- Underpayments are compared against contracted and ASP-based rates
- Net collection rate and days in A/R are reviewed every month
- Coders receive oncology-specific education each year
If you cannot check most of these boxes, outside specialty support is likely to pay for itself.
